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Abstract
Purpose: The syndrome of inappropriate antidiuresis is
often undertreated with most patients discharged with per-
sistent hyponatraemia. This study tested the hypothesis that
an endocrine input is superior to routine care in correcting
hyponatraemia and can improve patient outcomes.
Methods: This single-centre prospective-controlled inter-
vention study included inpatients admitted at a UK teaching
hospital, with serum sodium ≤ 127 mmol/l, due to syndrome
of inappropriate antidiuresis over a 6-month period. The
prospective intervention group (18 subjects with mean
serum sodium 120.7 mmol/l) received prompt endocrine
input, while the historical control group (23 patients with
mean serum sodium 124.1 mmol/l) received routine care.
The time needed for serum sodium increase ≥ 5 mmol/l was
the primary endpoint.
Results: The intervention group achieved serum sodium
rise by ≥5 mmol/l in 3.5 vs. 7.1 days in the control group
(P= 0.005). In the intervention group, the mean total serum
sodium increase was 12 mmol/l with only 5.8 % of patients
discharged with serum sodium< 130 vs. 6.3 mmol/l
increase (P< 0.001) and 42.1 % of the subjects discharged
with serum sodium< 130 mmol/l in the control group (P=
0.012). The mean length of hospital stay in the intervention
group (10.9 days) was signiﬁcantly shorter than in the
control group (14.5 days; P= 0.004).The inpatient mortality
rate was 5.5 % in intervention arm vs. 17.4 % in control
arm, but this difference was not statistically signiﬁcant.
Conclusions: Since the endocrine input improved time for
correction of hyponatraemia and shortened length of hos-
pitalisation, widespread provision of endocrine input should
be considered.
Keywords Hyponatraemia ● Syndrome of inappropriate
antidiuretic hormone secretion ● Vasopressin ● SIADH ●
Sodium
Introduction
Hyponatraemia is associated with considerable morbidity
and mortality [1–4], and carries a substantial economic
burden related to increased hospital resource utilisation,
length of hospital stay and risk of readmission [5, 6].
Syndrome of inappropriate antidiuresis (SIAD), the
commonest cause of hyponatraemia [7], is often under-
treated with recent large observational studies showing that
most patients are discharged with persistent hyponatraemia
[8–10].
Despite suboptimal standards of care for SIAD, no pro-
spective studies have examined the effect of widespread
provision of endocrine input on its management. Also there
is paucity of data about whether correcting hyponatraemia
can improve patient-related outcomes, such as mortality,
length of hospital stay, and readmission rate. The primary
hypothesis of our study was that prompt and intensive
endocrine input was superior to non-specialised ‘standard’
clinical care in correcting hyponatraemia with the primary
endpoint being time to achieve an increase in serum sodium
(sNa) by ≥5 mmol/l. Secondary objectives were:
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(1) to compare the total rise in sNa and the percentage of
patients discharged with sNa < 130 mmol/l between
intervention and control group
(2) to examine the effect of endocrine input on inpatient
mortality and length of hospital stay




This single-centre prospective-controlled intervention study
was conducted in a UK teaching hospital over a 6-month
period. During the ﬁrst 3-month period (1st October
2014–31st December 2014), all patients underwent ‘routine’
care (control group), while in the following 3-month period
(1st January 2015–31st March 2015), patients received
intensive endocrine input (intervention group). The ratio-
nale behind the use of a historical control was that under-
taking a randomised controlled trial in a real-life clinical
setting was considered impractical since clinicians might
often seek expert help from the investigators about patients
allocated to the control arm, resulting in possible ‘dilution’
of the control group with patients receiving the intervention.
The time required to achieve sNa increase of ≥5 mmol/l was
chosen as the primary endpoint since this magnitude of
correction can be sufﬁcient to improve symptoms of
hyponatraemia [11]. The study received ethical approval
from the London-Camden & Islington Research Ethics
Committee, and all subjects provided written informed
consent before participation.
Patient selection
All adults with sNa concentration ≤ 127 mmol/l both on
hospital admission and on the following day were identiﬁed
through an automated laboratory system. This cut-off sNa
value was selected because previous data from our cohort
showed a signiﬁcant upward inﬂection in inpatient mortality
below that threshold [4]. Among these patients, only sub-
jects who met all essential diagnostic criteria for SIAD,
including euvolaemia, hyponatraemia and low serum
osmolality with inappropriately raised urine osmolality and
sodium, normal adrenocortical reserve, and exclusion of
hypothyroidism [12, 13], participated in the study.
Subjects were excluded if they met any of the following
exclusion criteria: (1) aged< 18 years old, (2) presence of
hypervolaemic hyponatraemia, (3) hypovolaemic hypona-
traemia, (4) decompensated chronic liver disease, (5)
decompensated heart failure, (6) renal impairment with
serum creatinine >200 umol/l or receiving renal replace-
ment therapy, (7) uncontrolled hyperglycaemia with serum
glucose >15 mmol/l, (8) pregnancy/breastfeeding, (9)
receiving end-of-life care.
Taking into account preliminary data from our cohort
indicating a mean time of 5.5 days to reach the primary
endpoint of sNa rise ≥5 mmol/l and if standard deviation
(SD) for each arm is 1, power sample size was estimated, as
18 patients in each arm, in order to show 20% difference in
the primary endpoint (1.1 day) with 90 % power and 5 %
signiﬁcance level.
Control group
In real-life clinical practice, the mainstay of SIAD treatment
was ﬂuid restriction in combination with discontinuation of
offending drugs and treatment of underlying cause. When
hyponatraemia was refractory to ﬂuid restriction, some
patients were referred to endocrinologists, usually after
considerable delay, for consideration of pharmacological
therapy. In addition to ‘standard’ clinical care, all patients
had full biochemical work-up automatically performed with
the attending physicians being notiﬁed of the results.
Intervention group
The investigators, two senior endocrinologists with special
interest in hyponatraemia and a Research Nurse, provided
regular input on daily basis throughout hospitalisation to the
attending medical and nursing team under whose care the
patients remained. The intervention reﬂected best clinical
practice [14–16] without the utilisation of any novel diag-
nostic tests and therapeutic modalities.
Treatment options for SIAD included hypertonic saline,
ﬂuid restriction, demeclocycline and tolvaptan. First-line
treatment was ﬂuid restriction at a volume of 750–1000 ml/
day, apart from cases of severe hyponatraemic encephalo-
pathy requiring urgent correction with intravenous infusion
of 1.8 % sodium chloride under close supervision in a high
dependency or intensive care unit. In patients not
responding to ﬂuid restriction within 48–72 h,second-line
treatment, tolvaptan or demeclocycline was prescribed,
while urea was not utilised because of lack of availability
and absence of local experience in its use. Tolvaptan at a
starting dose of 15 mg once per day [17, 18] was used when
there was a clinical need for prompt hyponatraemia cor-
rection, for example to render a patient ﬁt for chemotherapy
or surgery, and in cases with likely short duration of SIAD,
for example pneumonia. Demeclocycline at a starting dose
of 900 mg per day in divided doses [19] was prescribed in
patients with high probability of requiring treatment for
longer than 1–2 weeks, such as malignant SIAD.
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Assessment of cognitive function
Taking into account the lack of validated tools to assess
symptoms in association with hyponatraemia, Mini-Mental
State Examination (MMSE), used extensively to follow the
course of cognitive changes over time [20, 21], was per-
formed in all participants of the intervention group at three
different time points; on admission, when sNa increased by
≥5 mmol/l from baseline and when sNa was ≥132 mmol/l.
Statistical analysis
Data were analysed using SPSS (version 21.0, Chicago, IL).
Continuous variables were expressed as mean± SD or per-
centages. Analysis of variance and Pearson’s χ2 test were
used to test differences between the intervention and the
control group. P-values of <0.05 were considered signiﬁcant.
Results
Demographic characteristics
The control group included 23 patients (11 males, 12
females) with a (mean± SD) age of 77.6± 10.7 years
compared to the intervention group of 18 subjects (12
males, 6 females) with a (mean± SD) age of 72.7± 10.2
years. There was no statistically signiﬁcant difference in age
and gender distribution across groups.
Speciality distribution, duration and aetiology of SIAD
There was a wide distribution of patients within different
specialities with most patients in both groups being under
the care of medical specialities. Chronic hyponatraemia,
deﬁned as most recent sNa value measurement within pre-
vious 6 months ≤132 mmol/l, was recorded in 34.8 % of
cases in the control arm and 44.5 % in the intervention arm
(P= 0.529). Different aetiologies of SIAD had similar
prevalence across groups, as shown in Table 1.
Baseline biochemical parameters
Serum Na concentration on admission was signiﬁcantly
lower in the intervention arm (120.7 ± 5.5 mmol/l) in
comparison with the control arm (124.1 ± 3.1 mmol/l) with
a P value of 0.017. All other biochemical parameters, apart
from serum osmolality, did not differ between two groups,
as shown in Table 2.
Endocrine input
All patients (100%) in the intervention group received endo-
crine input compared with 12/23 patients (52.2%) in the control
group (P= 0.001). The mean time interval between admission
and expert input in the intensive arm was 1.8 days, much
shorter than in the ‘routine’ care arm (5.7 days; P= 0.007).
Treatment of SIAD
In the group receiving ‘routine’ clinical care, 26.1 % of
patients had no speciﬁc treatment for SIAD vs. no untreated
cases in the intervention group (P = 0.027). The mean
number of therapeutic modalities used in the control arm
was 1.2, signiﬁcantly lower than in the intervention arm
(1.9; P= 0.041). The frequency of utilisation of different
therapeutic modalities is illustrated in Table 3.
Achievement of primary endpoint
The percentage of patients reaching the primary endpoint of
sNa rise ≥5 mmol/l was similar in the intervention group
(88.9 %) and in the control group (73.9 %; P= 0.230).
Table 1 Classiﬁcation of cases according to aetiology of SIAD
Aetiology Control group Intervention group P value
N= 23 (%) N= 18 (%)
Pulmonary illness 8 (34.8 %) 6 (33.3 %) 0.923
Idiopathic 6 (26.1 %) 6 (33.3 %) 0.613
Malignancy 5 (21.8 %) 2 (11.1 %) 0.369
Drug-induced 1 (4.3 %) 2 (11.1 %) 0.573
CNS disordera 2 (8.7 %) 1 (5.6 %) 0.702
Various 1 (4.3 %) 1 (5.6 %) 0.859
a Central nervous system pathology
Table 2 Baseline biochemical parameters in both study arms





Serum Mean± SD Mean± SD
Na (mmol/l) 124.1± 3.1 120.7± 5.5 0.017
K (mmol/l) 4.4± 0.7 4.5± 0.7 0.643
Urea (mmol/l) 4.9± 2.1 4.3± 2.0 0.365
Creatinine (umol/l) 58.7± 18.5 59.4± 20.5 0.916
Osmolality (mOsm/kg) 259.1± 8.0 252± 10.2 0.017
Urine
Na (mmol/l) 88.1± 48.8 65.3± 29.2 0.088
K (mmol/l) 36.6± 20.3 36.3± 20.2 0.968
Osmolality (mOsm/kg) 445.1± 138.0 401.6± 146.0 0.333
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However, subgroup analysis of control arm indicated that
all patients who did not reach the primary endpoint belon-
ged to the subgroup not receiving endocrine input.
The time interval needed for sNa rise ≥5 mmol/l was
3.5 days in the intervention group, almost half the time
(7.1 days) required in the control group (P= 0.005).
Rate of hyponatraemia correction
Three days following admission, a further decrease from the
baseline in sNa value was observed in 43.5 % of patients in
the control arm vs. 5.6 % of subjects in the intervention arm
(P= 0.007). The intervention group achieved signiﬁcantly
larger magnitudes of sNa correction than the control group,
as illustrated in Table 4.
Overly rapid correction of hyponatraemia, deﬁned as sNa
increase >12 mmol/l during any 24 h-period or >18 mmol/l
during any 48 h-period, was not recorded in the intervention
group, while one patient in the control group exceeded the
safe limits with sNa increase of 14 mmol/l in the ﬁrst 24 h
following tolvaptan initiation. No cases of osmotic
demyelination syndrome were documented.
sNa at discharge and patient outcomes
As illustrated in Fig. 1, the proportion of patients discharged
with moderate to severe hyponatraemia (sNa< 130mmol/l) in
the intervention group (5.8%) was signiﬁcantly lower than in
the control group (42.1%; P= 0.012). Subgroup analysis of the
control arm demonstrated that 30% of cases receiving endo-
crine input were discharged with moderate to severe hypona-
traemia vs. 55.5% of cases not receiving endocrine input.
The difference in the mean total sNa increase between
intervention arm (12mmol/l) and control arm (6.3 mmol/l)
was statistically highly signiﬁcant (P< 0.001). Further sub-
group analysis of the control arm showed higher total sNa rise
in patients with endocrine input (9± 3.8mmol/l) compared to
patients not receiving endocrine input (4.5± 4.8 mmol/l).
As shown in Table 5, the mean length of hospital stay in
the intervention group was signiﬁcantly shorter than in the
control group by 3.6 days (P= 0.004). The inpatient mor-
tality rate in the intervention group was 5.5 % in comparison
to 17.4% in the control group, but this difference did not
reach statistical signiﬁcance. Among the ﬁve fatal cases, two
patients, both in the ‘routine’ care group, had persistent
severe hyponatraemia at the time of death. The ﬁrst patient
did not receive any speciﬁc therapy for SIADH and died with
a sNa of 123mmol/l, while the second patient was not given
second-line treatment for SIADH despite failing to respond
to ﬂuid restriction and died with a sNa of 122mmol/l.
Effect of hyponatraemia correction on cognitive
function
Amongst 18 subjects in the intervention group, 4 patients
exhibited severe neurological symptoms, such as acute
changes in mental status and confusion, including 2 indi-
viduals with Glasgow Coma Score of 12. All these patients
Table 3 Frequency of utilisation of different therapeutic modalities
Treatment modality Control group Intervention group P value
N= 23 (%) N= 18 (%)
Drug discontinuation 5 (21.7 %) 7 (38.9 %) 0.231
Fluid restriction 16 (69.6 %) 18 (100 %) 0.010
Tolvaptan 5 (21.7 %) 3 (16.7 %) 0.684
Demeclocycline 2 (8.7 %) 3 (16.7 %) 0.439
Hypertonic saline 1 (4.3 %) 2 (11.1 %) 0.409
Table 4 Correction of sNa 2, 3 and 5 days following admission
Correction of sNa Control group Intervention
group
P value
N= 23 N= 18
2 days
Correction (mmol/l)a 0.3± 4.7 1.9± 3.5 0.234
Cases with sNa decrease (%) 12 (52.2 %) 4 (22.2 %) 0.051
3 days
Correction (mmol/l)a 0.5± 4.7 4.5± 3.3 0.004
Cases with sNa decrease (%) 10 (43.5 %) 1 (5.6 %) 0.007
5 days
Correction (mmol/l)a 1.9± 6.2 8.4± 3.3 <0.001
























sNa at discharge (mmol/l)
Control arm
Intervention arm
Fig. 1 Bar chart illustrating relative frequency distribution of sNa at
hospital discharge in both groups. Solid bars represent control arm,
while dotted bars represent intervention arm. Red bars show percen-
tage of patients discharged with moderate to severe hyponatraemia
(sNa< 130 mmol/l)
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showed marked improvement in symptomatology after sNa
increase. The remaining patients either had non-speciﬁc
mild symptoms (9 cases) or seemed asymptomatic (5 cases).
Improvement in MMSE score by ≥3 points when sNa
reached 132 mmol/l or increased by ≥5 mmol/l was recor-
ded in 38.9 % of subjects in the intervention arm, including
22.2 % of patients with incremental rise of ≥10 points.
Discussion
This study demonstrated that prompt endocrine input
reduced the time required to achieve clinically meaningful
sNa increase and led to signiﬁcantly shorter length of hos-
pital stay.
Several factors may explain the superiority of regular
endocrine input to ‘routine’ clinical care in correcting
hyponatraemia despite the fact that endocrine input was also
provided to almost half of patients in the ‘routine’ care arm.
A key factor may be that in the control arm, the average
time from presentation to referral for endocrine review was
longer than 5 days. Also considerable delay in therapy was
frequently observed in the control group, while patients in
the intervention group had prompt diagnosis and timely
initiation of appropriate treatment for SIAD. In the control
arm, around a quarter of patients did not receive any speciﬁc
treatment for SIAD, whereas there were no untreated cases
in the intervention arm. Another main factor differentiating
the treatment between groups was the frequency of using
ﬂuid restriction, being higher by 30 % in the intervention
compared to control arm. Despite the fact that only half of
all patients seem to respond to ﬂuid restriction, as shown in
Hyponatraemia Registry [10], its implementation in an
additional 30 % of cases in the intervention arm might have
resulted in signiﬁcant correction in around 15 % of cases.
The increased utilisation of ﬂuid restriction might have
made an even more signiﬁcant contribution to hypona-
traemia correction, taking into account that adherence to
ﬂuid restriction in the control group was often poor, while
in the intervention group, ﬂuid restriction was quite rigorous
with a mean oral intake of 800 ml/day and, more impor-
tantly, regular patient encouragement in combination with
bedside notices, detailed ﬂuid balance charts and removal of
excess bedside ﬂuids was used to promote patient com-
pliance. When ﬂuid restriction was ineffective, it was often
not followed with an additional therapy in the control arm in
contrast to second-line treatment with tolvaptan or deme-
clocycline being administered in the intervention group,
when indicated. Specialist care provision, apart from being
effective, was safe without limits for sodium correction
being exceeded in any cases and potentially cost-effective
with costly pharmacological agents such as tolvaptan being
utilised less often than in the control group.
In addition to superiority in correcting hyponatraemia,
expert input reduced by 3.6 days of the mean length of
hospitalisation. This ﬁnding becomes even more note-
worthy in light of the unprecedentedly low percentage of
patients (5.8 %) discharged with moderate or severe hypo-
natraemia, much lower than that observed in a recent mul-
ticentre UK observational study (23.8 %) [8] and in the
Hyponatraemia Registry (43 %) [9]. Moreover, the inter-
vention group had numerically lower inpatient mortality
rate (5.5 %) than the control group (17.4 %), but this dif-
ference was not statistically signiﬁcant. Finally, in a con-
siderable proportion of patients, prompt correction of
hyponatraemia resulted in rapid improvement of cognitive
function.
The main strength of our study was being the ﬁrst pro-
spective study assessing the effect of expert endocrine input
on correction of hyponatraemia and patient-related out-
comes. Also this intervention could be readily applicable in
everyday clinical practice since the investigators used only
tests and therapeutic measures routinely available. Taking
into account that ‘routine’ care at our institution included
referral to endocrinologists in a large proportion of cases
and that the subgroup of the control arm without specialist
input achieved much lower sNa increase than the subgroup
with endocrine input, our study might underestimate the
positive impact of the intervention.
However, this study had a number of limitations. First
and foremost, use of historical control instead of rando-
mising subjects to two arms, introduced a potential con-
founding bias. To minimise the possibility of authors’ bias
resulting in shorter length of stay in the intervention group,
caring clinical teams responsible for patient care took all
clinical decisions such as when a patient should be dis-
charged, with the exception for decisions related to hypo-
natraemia management. In fact, in a few cases, especially
under surgical speciality, the investigators’ input contributed
to prolongation rather than shortening of hospitalisation by
strongly recommending against hospital discharge, based on
Table 5 Patient outcomes at discharge
Outcomes Control arm Intervention arm P value
N= 23 N= 18
Total sNa risea
(mmol/l)b
6.3± 0.3 12± 6.8 <0.001
Inpatient mortality rate 4/23 (17.4 %) 1/18 (5.5 %) 0.250
Length of stay (days)b 14.5± 7.9 10.9± 5.3 0.004
Cases discharged on
therapy
3/19 (15.8 %) 10/17 (58.8 %) 0.004
Readmission rate 5/19 (26.3 %) 4/17 (23.5 %) 0.970
a calculated as [sNa at discharge or death−baseline sNa]
b Mean± SD
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high probability of hyponatraemia recurrence and continu-
ing need for close electrolyte monitoring. Also the inter-
vention arm was studied immediately after the control arm
in order to ameliorate differences in standards of medical
and nursing care, discharge policy, characteristics of hos-
pital population, and clinicians’ prescribing habits. Another
possible confounder was the seasonal effect on the dis-
tribution of SIAD aetiologies. However, the frequency of
pulmonary infection-related SIAD cases was similar across
groups since the ﬁrst arm of the study took place in late
autumn and at the beginning of winter, while the second
arm in late winter and at the beginning of spring. A further
limitation of this study was the small sample size which had
adequate power to detect differences in time for correction
of hyponatraemia, but it was not powered to identify dif-
ferences, unless large, in mortality rate and length of stay.
The small sample size might also increase the probability of
type II statistical error if it introduced confounding through
signiﬁcant differences in the underlying aetiology of SIAD.
However the proportion of short duration SIAD cases with a
high probability for prompt correction, such as pulmonary
infection-related and drug-induced SIAD, was almost
identical between intervention and control arm. Addition-
ally, all cases in the intervention arm with drug-induced
SIAD, a condition which usually responds very well to drug
withdrawal, did not discontinue the, regarded as essential,
offending drug, but were treated with ﬂuid restriction.
Finally, the generalisability of the positive impact of
endocrine input was questionable since it might be highly
dependent on the clinical acumen, knowledge and skills of
the physicians providing expert input, especially since
investigators had extensive experience and expertise in
management of SIAD.
This study showed that improving clinical practice led to
effective and safe hyponatraemia correction and better
patient outcomes. It could be argued that the better standard
of care achieved through regular endocrine input might
be also met by ‘generalists’. However the consistently
suboptimal management of SIAD demonstrated in numer-
ous contemporary studies [8–10] [22] indicated that
wider provision of expert input should be considered. To
effectively deliver this service, multidisciplinary hypona-
traemia teams should be developed. These teams should be
led by endocrinologists or other physicians with a special
interest in hyponatraemia, such as nephrologists, depending
on local expertise. In view of the high prevalence of
hyponatraemia, we could consider a 2-tier model of care
incorporating electronic alert systems, recently tested
with promising results in acute kidney injury [23, 24],
with regular involvement of hyponatraemia teams in
selected cases.
Our proposed algorithm for optimal SIAD management
includes various therapeutic options with individualised
treatment decisions being based on several factors, includ-
ing duration and degree of hyponatraemia, severity of
symptoms, the capacity of the nephron to excrete free water,
urine osmolality, the safety and efﬁcacy of each treatment
modality, cost implications of each therapy and patient
compliance [25]. The only treatment modality indicated in
patients with severe symptoms related to hyponatraemia,
such as seizures, reduced Glasgow Coma Scale and coma, is
infusion of hypertonic saline. Treatment with 3 % sodium
chloride should commence as bolus of 100 ml over
10–15 min, which should be repeated, if needed, and be
followed by intravenous continuous infusion [15]. In the
absence of severe hyponatraemic encephalopathy, we aim
for an increase in sNa concentration by 4–5 mmol/l/day and
not exceeding the limit of 10 mmol/l/day [14] [16] . First-
line therapy encompasses treatment of the underlying cause
of SIAD and ﬂuid restriction. Restriction of all ﬂuid intake
should be titrated according to the Furst27 formula using the
urine/plasma electrolyte ratio (U/P) = (UNa + UK)/(PNa +
PK), for example 500 ml/day if U/P is 0.5–1.0 and 1000 ml/
day if U/P is <0.5 [26]. If urine electrolytes are not readily
available, we impose ﬂuid restriction at 750–1000 ml/day.
We recommend tolvaptan use as ﬁrst-line treatment in two
groups of SIADH patients; ﬁrst, if there is a clinical need for
prompt correction of hyponatraemia, for example to render
a patient ﬁt for chemotherapy or surgery, and second, in
cases when ﬂuid restriction is highly unlikely to be effec-
tive, evidenced by U/P> 1.0 or urine osmolality> 500
mOsm/kg H2O [15]. Tolvaptan should be strongly con-
sidered as second-line therapy if a patient has not responded
to ﬂuid restriction, deﬁned as sNa increase of
≤3 mmol/l over 48 h. We recommend tolvaptan use only
under the supervision of an endocrinologist or nephrologist
with patients on tolvaptan maintaining ad libitum ﬂuid
intake and not receiving any other concomitant treatment
for hyponatraemia. At our institution, we start tolvaptan at a
dose of 15 mg for baseline sNa ≥ 125 mmol/l and at 7.5 mg,
half the recommended initiating dose, for sNa< 125mmol/l,
since this low starting dose may be associated with lower
risk of overly rapid correction, while it retains its efﬁcacy
[27–29]. Serum Na concentration should be closely mon-
itored no later than 4–6 h after treatment initiation and at
regular 6-h intervals, at least, during the ﬁrst 24 h of ther-
apy. If serum Na increase exceeds 6 mmol/l at 6 h or
8 mmol/l at any time point between 7 and 18 h following
tolvaptan initiation or 10 mmol/l in 24 h, then free water
losses are replaced with administration of 5 % dextrose in
water at a volume equal to urine output in order to prevent
further correction. In cases when reversal of overly rapid
correction is warranted, larger volumes of hypotonic ﬂuids
are prescribed [16]. Finally and in light of the high cost
associated with long-term tolvaptan use, we prescribe
demeclocycline at a starting dose of 300 mg three times
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per day in patients with likely long duration of SIAD, such
as malignant SIAD.
Our ﬁndings highlight the need for multicentre
prospective-controlled studies to examine the impact of
specialist input on clinical endpoints such as mortality rate,
length of stay, symptoms and readmission rate. Since SIAD
represents a potential target for intervention to reduce
healthcare expenditures for a large population of inpatients,
it is also essential to test the cost-effectiveness of wide-
spread provision of expert input, taking into account on the
one hand potential reduction in length of hospitalisation and
readmission rate, and on the other hand additional cost
related to clinical and nursing time and cost of pharmaco-
logical therapies. Finally, studies are warranted to develop
tools measuring hyponatraemia-speciﬁc symptoms which
could be used longitudinally for assessment of symptoms
and neurocognitive performance in response to any sodium-
correcting therapy.
In conclusion, these preliminary data demonstrated that
intensive endocrine input not only was superior to ‘routine’
care in correcting hyponatraemia, but also improved patient-
important outcomes such as length of hospital stay and
symptoms. If these results could be generalised, provision
of systematic endocrine care for patients with SIAD should
be widely adopted to improve clinical outcomes and
potentially reduce utilisation of hospital resources.
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